Arcus Biosciences EPS - Earnings per Share 2017-2023 | RCUS
Arcus Biosciences eps - earnings per share from 2017 to 2023. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Arcus Biosciences Annual EPS |
| 2022 |
$-3.71 |
| 2021 |
$0.71 |
| 2020 |
$-2.24 |
| 2019 |
$-1.93 |
| 2018 |
$-1.43 |
| 2017 |
$-29.03 |
| 2016 |
$-20.80 |
| Arcus Biosciences Quarterly EPS |
| 2023-03-31 |
$-1.09 |
| 2022-12-31 |
$-0.92 |
| 2022-09-30 |
$-0.90 |
| 2022-06-30 |
$-0.93 |
| 2022-03-31 |
$-0.96 |
| 2021-12-31 |
$3.99 |
| 2021-09-30 |
$-1.11 |
| 2021-06-30 |
$-1.09 |
| 2021-03-31 |
$-1.08 |
| 2020-12-31 |
$-0.71 |
| 2020-09-30 |
$0.03 |
| 2020-06-30 |
$-0.93 |
| 2020-03-31 |
$-0.63 |
| 2019-12-31 |
$-0.37 |
| 2019-09-30 |
$-0.51 |
| 2019-06-30 |
$-0.64 |
| 2019-03-31 |
$-0.41 |
| 2018-12-31 |
$0.51 |
| 2018-09-30 |
$-0.25 |
| 2018-06-30 |
$-0.32 |
| 2018-03-31 |
$-1.37 |
| 2017-12-31 |
$-6.57 |
| 2017-09-30 |
$-11.86 |
| 2017-06-30 |
$-5.64 |
| 2017-03-31 |
$-4.96 |
| 2016-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.536B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
